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ILLUSTRATIVE CASE
Case 1: A healthy 25-year-old woman 
comes to see you because she’s worried 
about getting pregnant. She’s been on an 
extended-cycle oral contraceptive (OC) for 
several months and is happy to have her 
period only once every 3 months, but she 
frequently forgets to take her pill. 
What can you offer that will give her the 
benefi ts of an extended-cycle OC, without 
the risk of pregnancy she incurs each time 
she misses a pill? 
Case 2: You started a healthy 18-year-old 
on the transvaginal ring 6 months ago. After 
counseling, she opted for continuous cycling, 
so she inserts a new ring right after she re-
moves the old one, on the same date each 
month. Although she likes the ring, she’s dis-
turbed by a recent increase in breakthrough 
bleeding. What can you recommend to de-
crease the bleeding?
Clinicians have long known that the traditional 21/7 OC cycle is not necessary for safety or effi -
cacy. More recently, many women have 
been happy to learn that there is no 
physiologic reason to have a monthly 
period when they’re using combination 
hormonal contraception. They’re also 
happy to discover that fewer periods 
often mean fewer premenstrual mood 
swings, episodes of painful cramping, 
and instances of other troublesome 
symptoms. 
❚  The transvaginal ring 
is often overlooked 
The US Food and Drug Administration 
(FDA) has approved 2 combination OCs 
for extended-cycle use and 1 for con-
tinuous use. But any monophasic OC 
can be used off-label for extended or 
continuous cycling to decrease bleeding 
frequency. So, too, can the transvaginal 
Recommend continuous or 
extended use of the trans-
vaginal contraceptive ring to 
women who want fewer days 
of menstrual bleeding and 
have trouble remembering to, 
or prefer not to, take a daily 
pill. If breakthrough bleeding 
is troublesome, suggest a 
4-day ring-free interval.1 
Strength of recommendation 
B: Based on a single randomized controlled trial (RCT) with 
<80% follow up. 
Sulak PJ, Smith V, Coffee A, et al. Frequency 
and management of breakthrough bleeding with 
continuous use of the transvaginal contraceptive 
ring: a randomized controlled trial. Obstet 
Gynecol. 2008;112:563-571.
Practice changer 
When to suggest this 
OC alternative 
Consider continuous use of the vaginal ring for women 
who want minimal bleeding and maximal protection. 
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Which of the 
following best 
describes your current 
practice regarding 
the transvaginal 
contraceptive ring?
❑  I prescribe the ring based 
on the manufacturer’s 
instructions (21/7 cycle) 
only. 
❑  When I prescribe the 
ring, I discuss extended/
continuous use with the 
patient.
❑  I have never prescribed 
the ring, but would 
consider doing so based 
on patient interest. 
❑  I do not plan to prescribe 
the contraceptive ring.
Go to www.jfponline.com 
and take our Instant Poll
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contraceptive ring (NuvaRing), an in-
frequently used contraceptive. (Accord-
ing to 1 study, just 5.7% of US women 
using contraception used either the 
ring or the patch.2) The ring has been 
studied for extended use,3 but does not 
have FDA approval for longer-term 
regimens. 
NuvaRing is a fl exible, transpar-
ent device that contains the progestin 
etonogestrel and ethinyl estradiol. The 
manufacturer recommends a 21/7 cycle, 
inserting the ring in the vagina and leav-
ing it in place for 3 weeks, removing it for 
1 week, and then inserting a new ring.4 
The ring is well suited to women who 
have no contraindications to hormonal 
contraception but have diffi culty remem-
bering to take a pill every day—or simply 
prefer the convenience of less frequent 
dosing. 
While the ring has been found to be 
effective and tolerable when used with-
out a hormone-free interval—28-, 49-, 
91- and 364-day dosing has been stud-
ied—breakthrough bleeding or spotting 
is a frequent side effect of extended-cy-
cle hormonal contraception. In 1 study, 
43% of women on a 49-day ring cycle 
experienced breakthrough bleeding, 
compared with 16% of those on a 28-
day cycle.3 
High satisfaction, low risk
Nonetheless, women who use the 
transvaginal ring often report high 
satisfaction. One study found that 
61% of women were very satisfi ed 
with this method of contraception, 
compared with 34% of triphasic OC 
users (P<.003).5 The risk of pregnancy 
(1-2 pregnancies per 100 women-years 
of use, according to the manufacturer4) 
and the risk of venous thromboembolism 
(10-30 in 100,000 vs 4-11 in 100,000 
nonpregnant women who are not using 
hormonal contraception) are compara-
ble to that of women using OCs.6,7 The 
risk of other severe side effects associ-
ated with the vaginal ring is comparable 
to that of OCs, as well.
STUDY SUMMARY
❚  An effective option that
women used post-trial
This RCT recruited women between the 
ages of 18 and 45 years who had been 
using combination hormonal contracep-
tives—OCs, the transdermal patch, or 
the transvaginal ring. All had been on a 
21/7 cycle for at least 2 months. Exclu-
sion criteria included a body mass index 
≥38 kg/m2, smoking >10 cigarettes per 
day, use of other estrogen- or phytoestro-
gen-containing products, and the pres-
ence of ovarian cysts >2.5 cm or endo-
metrial thickness >8 mm. Women who 
wanted to get pregnant within a year 
were also excluded. 
The study began with a baseline phase 
during which participants completed one 
21/7 cycle with the ring for those using 
the ring prior to the study or two 21/7 cy-
cles for those using the pill or patch pri-
or to the study. Daily fl ow was assessed 
during this initial phase, using a scale of 
0 to 4, with 4 being the heaviest. Women 
who completed this phase and wanted to 
continue using the ring (N=74) were then 
randomized into 2 groups (n=37) for the 
6-month extended phase. 
Group 1 was assigned to use the con-
traceptive ring with no hormone-free 
days. Participants were instructed to 
replace the rings monthly, on the same 
calendar day of the month. Group 2 also 
used the ring on a continuous basis with 
monthly replacement, but those who 
experienced breakthrough bleeding for 
more than 5 days were permitted to re-
move the ring for 4 days. Women in both 
groups kept a daily diary of ring usage, 
degree of menstrual fl ow, and symptom-
atology, including pelvic pain, headaches, 
and mood.
Most subjects were white (76%), 
nonsmokers (84%), and unmarried 
(68% in Group 1 and 57% in Group 2), 
with an average age of 28 to 29 years. 
Eight patients (22%) in Group 1 with-
drew from the study prior to completing 
the 6-month extended phase, 4 of them 
because of side effects. Only 1 woman 
The risk of venous 
thromboembolism 
associated with the 
ring is about the 
same as that of oral 
contraceptives—10 
to 30 per 100,000 
users.
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withdrew from Group 2, because of plans 
for pregnancy. No one became pregnant 
while using the ring.
Hormone-free interval reduced bleed-
ing. In Group 1, the average daily fl ow 
score was slightly reduced with con-
tinuous use (from 0.33 during the 21/7 
baseline phase to 0.21 in the 6-month 
extended phase), but researchers report-
ed no signifi cant difference in fl ow-free 
days. On average, 85% of the days were 
fl ow-free in the 21/7 phase, vs 89% in the 
extended phase. 
In Group 2, fl ow-free days increased, 
from 83% in the baseline phase to 95% 
in the extended phase, and average fl ow 
scores fell from 0.38 to 0.17. 
Overall, the 65 participants who 
completed 6 months of continuous ring 
use had fewer bleeding days per month—
1.8 days, on average, vs 3.3 days during 
the initial 21/7 phase, but more days of 
spotting per month (2.5 vs 1.8 days). 
There was no difference between Groups 
1 and 2 in pelvic pain, headache, or mood 
scores, and no signifi cant difference in 
headache or mood scores between the 
baseline and continuous phases of the 
trial. Pelvic pain scores were lower dur-
ing the extended phase, however—0.18 
vs 0.32 on a scale of 0 to 10. 
A high continuation rate. After the 
6-month extended phase, 57 of the 65 
remaining participants chose to continue 
using the ring for contraception, on a 
continuous dosing basis—a continuation 
rate of 88%. But more than half of the 
women who chose to stick with the ring 
(57%) decided not to take advantage of 
the 4-day hormone-free interval to man-
age breakthrough bleeding or spotting, 
regardless of original group assignment. 
WHAT’S NEW?
❚  The ring moves further 
mainstream
Continuous or extended use of the trans-
vaginal ring may be a new idea for many 
patients—and physicians. But the idea 
may catch on in light of this study’s fi nd-
ings. Given the high rate of unwanted 
pregnancy in the United States, many 
women may benefi t from a contraceptive 
that is as safe and effective as an OC but 
doesn’t involve a daily pill. 
CAVEATS
❚  Side effects, off-label 
concerns
In 2005, Oddsson et al found that wom-
en who used the ring reported more vagi-
nitis and more leukorrhea than women 
who used OCs; conversely, they reported 
less nausea and less acne. Other side ef-
fects that are common to hormonal con-
traceptives, such as headache and weight 
gain, occurred at similar rates among 
women using the ring and OCs.6 
However, the high proportion of pa-
tients who elected to keep using the ring 
at the end of the study by Sulak et al sug-
gests that its side effects are acceptable.1 
As with all contraception, however, pa-
tient preference is a key consideration. 
The study population was highly moti-
vated, particularly since women who had 
diffi culty with this means of contracep-
tion dropped out after the baseline phase 
of the trial. 
Off-label use. Pharmacokinetic re-
search involving the contraceptive ring 
has shown that hormone levels required 
to protect against pregnancy persist for 
at least 35 days after it is placed in the 
vagina.8 The manufacturer has data only 
to confi rm contraceptive effi cacy for up 
to 28 days and therefore does not recom-
mend use beyond 4 weeks.4 
This study highlights another off-
label issue: Women in Group 2, who were 
allowed to remove the ring for 4 day-in-
tervals to decrease breakthrough bleed-
ing, were instructed to reinsert the same 
ring after 4 days and keep it in place until 
the next scheduled replacement date. But 
the manufacturer does not recommend 
reinsertion of a ring that has been out of 
the body for more than 3 hours. In my 
practice (KR), women are generally un-
willing to store and replace a ring, prefer-
ring to place a new one after removal for 
more than a few hours. 
After the 6-month 
trial of extended 
use of the ring, 
88% of the women 
continued to use it 
for contraception.
C O N T I N U E D
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Funding. The research was funded 
by an unrestricted educational grant 
from Organon, Inc, the manufacturer of 
NuvaRing, which included salary sup-
port for 5 of the 6 authors. The published 
study gives no additional information 
about the involvement of the pharmaceu-
tical company. 
Contraindications, drug interactions. 
As with other combined hormonal con-
traceptives, women who have a history 
of venous thromboembolism, headaches 
with focal neurological symptoms, severe 
hypertension, breast or endometrial can-
cer, or liver disease, and smokers older 
than 35 years should not use the contra-
ceptive ring.4 In addition, women need 
to be aware that a number of medica-
tions—griseofulvin, rifampin, phenytoin, 
carbamazepine, and herbal products 
containing St. John’s Wort, among oth-
ers—may reduce the effectiveness of the 
contraceptive ring.4
CHALLENGES TO IMPLEMENTATION
❚  Going off-label
isn’t for everyone 
When it comes to choosing a contracep-
tive method, patient preference is para-
mount. Some women may not be com-
fortable inserting or removing the ring 
and should be counseled on other forms 
of contraception. Women who prefer to 
bleed every month should not use ex-
tended cycling. Similarly, some physicians 
may not be comfortable recommending 
an off-label use of the ring. 
Those who are comfortable making 
the recommendation should be prepared 
to educate patients about this method 
of contraception and to discuss the ben-
efi ts of extended or continuous use of 
the ring. For some women, the memory-
triggering mechanism of changing the ring 
on the same date each month may boost 
adherence. For others, replacing the ring 
every 28 days may be acceptable—again, 
depending on patient preference. ■
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Women who use 
the ring report more 
vaginitis and more 
leukorrhea than 
women on OCs, but 
less nausea and 
acne.
Changing the ring on the same date each month may 
boost adherence for some women.
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Should she try continuous use? 
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